SCHEMBL6930770

SCHEMBL6930770

C(#CCN1CCOCC1)CN1CCCC1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.70
ALDH1A1 P00352 3/20 0.53
RECQL P46063 1/20 0.53
POLB P06746 1/20 0.53
GAA P10253 1/20 0.53
CHRM2 P08172 5/20 0.48
CHRM4 P08173 5/20 0.48
CHRM5 P08912 5/20 0.48
CHRM1 P11229 5/20 0.48
CHRM3 P20309 5/20 0.48
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KDM4E B2RXH2 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6929250 0.92 POLB (0.59) LMNAALDH1A1RECQLPOLBGAA
SCHEMBL892987 0.84 LMNA (1.00) LMNAALDH1A1CHRM2CHRM4CHRM5
SCHEMBL1745361 0.82 ALDH1A1 (0.66) LMNAALDH1A1RECQLPOLBGAA
SCHEMBL27486201 0.81 POLB (0.50) LMNAALDH1A1RECQLPOLBGAA
SCHEMBL21192307 0.81 POLB (0.50) LMNAALDH1A1RECQLPOLBGAA
SCHEMBL12374731 0.81 ALDH1A1 (0.50) LMNAALDH1A1RECQLPOLBGAA
SCHEMBL17392944 0.81 POLB (0.50) LMNAALDH1A1RECQLPOLBGAA
SCHEMBL3274800 0.81 POLB (0.50) LMNAALDH1A1RECQLPOLBGAA
SCHEMBL1469845 0.81 POLB (0.59) LMNAALDH1A1RECQLPOLBGAA
Hydrochloric Acid SCHEMBL6081619 0.81 LMNA (0.93) LMNAALDH1A1CHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017395-A4 METHOD FOR TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME MERCK & CO INC (US) 2003-06-04 EP disclosed
EP-1017395-A1 METHOD FOR TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME Merck & Co., Inc. (US) 2000-07-12 EP disclosed
EP-1001780-A1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MANIA MERCK SHARP & DOHME LTD. (GB) 2000-05-24 EP disclosed
EP-1001779-A1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR DISORDERS MERCK SHARP & DOHME LTD. (GB) 2000-05-24 EP disclosed
EP-0977572-A1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS MERCK SHARP & DOHME LTD. (GB) 2000-02-09 EP disclosed
EP-0977573-A1 USE OF AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR TREATING OBESITY MERCK SHARP & DOHME LTD. (GB) 2000-02-09 EP disclosed
EP-0929303-A2 CNS-PENETRANT NK-1 RECEPTOR ANTAGONISTS AS ANTIDEPRESSANT AND/OR AN ANTI-ANXIETY AGENT MERCK SHARP & DOHME LTD. (GB) 1999-07-21 EP disclosed
WO-1999009987-A1 METHOD FOR TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME MERCK & CO., INC. (US) 1999-03-04 WO disclosed
WO-1999007374-A1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR MERCK SHARP & DOHME LIMITED (GB) 1999-02-18 WO disclosed
WO-1999007376-A1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MANIA MERCK SHARP & DOHME LIMITED (GB) 1999-02-18 WO disclosed
WO-1999007375-A1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR DISORDERS MERCK SHARP & DOHME LIMITED (GB) 1999-02-18 WO disclosed
WO-1998047514-A1 USE OF AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR TREATING OBESITY MERCK SHARP & DOHME LIMITED (GB) 1998-10-29 WO disclosed
WO-1998047513-A1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS MERCK SHARP & DOHME LIMITED (GB) 1998-10-29 WO disclosed
WO-1998015277-A2 CNS-PENETRANT NK-1 RECEPTOR ANTAGONISTS AS ANTIDEPRESSANT AND/OR AN ANTI-ANXIETY AGENTS MERCK SHARP & DOHME LIMITED (GB) 1998-04-16 WO disclosed